INT32515

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1987
Last Reported 2011
Negated 2
Speculated 1
Reported most in Abstract
Documents 82
Total Number 84
Disease Relevance 28.10
Pain Relevance 17.46

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (B4GALNT1) plasma membrane (B4GALNT1) carbohydrate metabolic process (B4GALNT1)
Anatomy Link Frequency
blood 4
brain 3
neuronal 3
osteoclasts 2
platelet 2
B4GALNT1 (Homo sapiens)
Pain Link Frequency Relevance Heat
aspirin 10 100.00 Very High Very High Very High
cINOD 28 99.92 Very High Very High Very High
antagonist 35 99.84 Very High Very High Very High
tetrodotoxin 3 99.84 Very High Very High Very High
Calcium channel 10 99.80 Very High Very High Very High
COX2 5 99.80 Very High Very High Very High
cOX1 3 99.80 Very High Very High Very High
Serotonin 15 99.74 Very High Very High Very High
Inflammation 67 99.70 Very High Very High Very High
acular 35 99.58 Very High Very High Very High
Disease Link Frequency Relevance Heat
Hypercalcemia 29 99.80 Very High Very High Very High
INFLAMMATION 83 99.70 Very High Very High Very High
Porphyria 4 99.44 Very High Very High Very High
Conjunctiva Disease 2 99.44 Very High Very High Very High
Mucopolysaccharidoses 9 99.36 Very High Very High Very High
Cv General 3 Under Development 75 99.28 Very High Very High Very High
Nociception 11 99.28 Very High Very High Very High
Toxicity 71 99.14 Very High Very High Very High
Migraine Disorders 4 99.04 Very High Very High Very High
Myocardial Infarction 28 98.80 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
N(G)-nitro-l-arginine (l-NOARG), a NO synthase inhibitor, abolished the relaxations to nerve stimulation, which were partially reversed by the substrate of NO synthesis l-arginine. l-NOARG failed to modify the relaxations to exogenous NaNO(2).
Negative_regulation (inhibitor) of NO synthase in nerve
1) Confidence 0.43 Published 2010 Journal Neurosci. Lett. Section Abstract Doc Link 20417249 Disease Relevance 0 Pain Relevance 0.18
Canavanine, an NO synthase inhibitor, inhibited NO generation.
Negative_regulation (inhibitor) of NO synthase
2) Confidence 0.43 Published 1995 Journal Physiol Chem Phys Med NMR Section Abstract Doc Link 7568414 Disease Relevance 0 Pain Relevance 0.73
Blockers of NO synthase could be useful in therapy for the urinary incontinence produced by intrinsic sphincteric deficiency.
Negative_regulation (Blockers) of NO synthase associated with overactive bladder
3) Confidence 0.42 Published 2010 Journal Neurosci. Lett. Section Abstract Doc Link 20417249 Disease Relevance 0.10 Pain Relevance 0.17
These changes may be, in part, due to the reduction of sialidase and UDP-N-acetylgalactosamine:GM3 N-acetylgalactosaminyltransferase (GalNAc-T) activities in MPS IIID caprine brain.
Negative_regulation (reduction) of GalNAc-T in brain associated with mucopolysaccharidoses
4) Confidence 0.41 Published 2001 Journal Mol. Genet. Metab. Section Abstract Doc Link 11243730 Disease Relevance 1.10 Pain Relevance 0.11
In conclusion, aflatoxin may increase the amplitude and frequency of contractions by increasing muscarinic activity or by decreasing NO synthase and/or release in proximal colon and by increasing muscarinic activity in the distal colon.
Negative_regulation (decreasing) of NO synthase in colon
5) Confidence 0.40 Published 2008 Journal Food Chem. Toxicol. Section Abstract Doc Link 18620790 Disease Relevance 0 Pain Relevance 0.08
Combined administration of TX antagonists and TX synthase inhibitors offers a theoretical advantage over aspirin which may ultimately justify their place in the therapy of vascular disease in humans.
Negative_regulation (inhibitors) of synthase associated with aspirin, antagonist and increased venous pressure under development
6) Confidence 0.37 Published 1987 Journal Adv. Prostaglandin Thromboxane Leukot. Res. Section Abstract Doc Link 2959047 Disease Relevance 0.29 Pain Relevance 0.20
Patients with unrecognized cobalamin deficiency may be particularly susceptible to brief exposures to nitrous oxide, which inactivates the cobalamin-dependent enzyme methionine synthase and may cause a myeloneuropathy.
Negative_regulation (inactivates) of synthase
7) Confidence 0.37 Published 1995 Journal Neurology Section Abstract Doc Link 7644061 Disease Relevance 0.37 Pain Relevance 0.17
The effects of morphine on cell conformation were blocked in the presence of N-nitro-L-arginine, a nitric oxide synthase inhibitor.
Negative_regulation (inhibitor) of synthase associated with morphine
8) Confidence 0.37 Published 1996 Journal J. Immunol. Section Abstract Doc Link 8648133 Disease Relevance 0 Pain Relevance 0.92
Nitroglycerine administration results in a delayed migraine-like headache in migraine patients but not in control patients, and a nonspecific nitric oxide synthase inhibitor aborted migraine at 2 hours in the majority of tested migraine patients compared to controls.
Negative_regulation (inhibitor) of synthase
9) Confidence 0.36 Published 2001 Journal Neurologist Section Body Doc Link 12803669 Disease Relevance 0.07 Pain Relevance 0
L-Citrulline also reversed the inhibition produced by another NO synthase inhibitor, L-nitro monomethyl arginine.
Negative_regulation (inhibitor) of NO synthase
10) Confidence 0.33 Published 1994 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 7516967 Disease Relevance 0 Pain Relevance 0.06
These results suggest that L-citrulline is able to overcome the inhibition of NO synthase by NO synthase inhibitors in the guinea pig trachea and human bronchus.
Negative_regulation (inhibition) of NO synthase in bronchus
11) Confidence 0.33 Published 1994 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 7516967 Disease Relevance 0 Pain Relevance 0
The suppressive mechanisms occur not only by pretranslational inhibition of eNOS expression but also by a posttranslational decrease in endothelial NO synthase activity due to a reduction in intracellular calcium levels.


Negative_regulation (decrease) of synthase
12) Confidence 0.26 Published 2005 Journal Crit. Care Med. Section Body Doc Link 15891334 Disease Relevance 0 Pain Relevance 0
These relaxation responses were abolished by an inhibitor of NO synthase or tetrodotoxin proving that they were nitrergic in nature and neuronal in origin.
Negative_regulation (inhibitor) of NO synthase in neuronal associated with tetrodotoxin
13) Confidence 0.26 Published 2004 Journal Int. J. Impot. Res. Section Abstract Doc Link 14961056 Disease Relevance 0 Pain Relevance 0.14
The suppressive mechanisms occur not only by pretranslational inhibition of eNOS expression but also by a posttranslational decrease in endothelial NO synthase activity due to a reduction in intracellular calcium levels.


Negative_regulation (reduction) of synthase
14) Confidence 0.19 Published 2005 Journal Crit. Care Med. Section Body Doc Link 15891334 Disease Relevance 0 Pain Relevance 0
Results of an assay by reverse-transcription polymerase chain reaction showed that ketamine significantly inhibited levels of endothelial NO synthase messenger RNA.
Negative_regulation (inhibited) of synthase
15) Confidence 0.19 Published 2005 Journal Crit. Care Med. Section Body Doc Link 15891334 Disease Relevance 0 Pain Relevance 0
These effects were significantly and stereospecifically attenuated by NG-nitro-L-arginine methyl ester, an inhibitor of NO synthase, and restored by L-arginine, the substrate for NO synthase (P < 0.05).
Negative_regulation (inhibitor) of NO synthase
16) Confidence 0.13 Published 1995 Journal J. Appl. Physiol. Section Abstract Doc Link 8567541 Disease Relevance 0 Pain Relevance 0.27
Subjects were instrumented for continuous brachial artery infusion of saline (control condition) or combined infusion of N(G)-nitro-L-arginine methyl ester (L-NAME) and ketorolac (drug condition) to inhibit NO synthase and cyclooxygenase, respectively.
Negative_regulation (inhibit) of NO synthase in brachial artery associated with acular
17) Confidence 0.12 Published 2005 Journal Am. J. Physiol. Heart Circ. Physiol. Section Abstract Doc Link 15345484 Disease Relevance 0.16 Pain Relevance 0.10
Indeed, Wilkinson et al. [17] and Schmitt et al. [18] have demonstrated that intra-arterial infusion of NG-monomethyle-L-arginine (L-NMMA), a NO synthase inhibitor, increased pulse wave velocity (PWV) of iliac artery in animals and humans, respectively, and the effect of acetylcholine, a drug that stimulate endothelial NO production, on PWV was inhibited by coinfusion of L-NMMA.
Negative_regulation (inhibitor) of NO synthase in iliac artery
18) Confidence 0.11 Published 2008 Journal The Open Cardiovascular Medicine Journal Section Body Doc Link PMC2570577 Disease Relevance 0.26 Pain Relevance 0
A second site was treated with NG-nitro-L-arginine methyl ester (L-NAME) to inhibit NO synthase.
Negative_regulation (inhibit) of NO synthase
19) Confidence 0.08 Published 2005 Journal J. Appl. Physiol. Section Abstract Doc Link 15649880 Disease Relevance 0.15 Pain Relevance 0.39
We measured forearm blood flow (FBF) using venous occlusion plethysmography in 50 healthy volunteers (27 +/- 1 yr) in response to brachial artery infusion of ACh or BK in the absence and presence of inhibitors of NO synthase [NOS; with NG-monomethyl-L-arginine (L-NMMA)] and cyclooxygenase (COX; with ketorolac).
Negative_regulation (inhibitors) of NO synthase in brachial artery associated with acular
20) Confidence 0.05 Published 2005 Journal J. Appl. Physiol. Section Abstract Doc Link 15563630 Disease Relevance 0 Pain Relevance 0.44

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox